Full Press Release Details
linvoseltamab bla accepted for fda review for the treatment of relapsed refractory multiple myeloma.
REGN
linvoseltamab bla accepted for fda review for the treatment of relapsed refractory multiple myeloma
Key Takeaway: linvoseltamab bla accepted for fda review for the treatment of relapsed refractory multiple myeloma